Share on Facebook
Share on Twitter
Share on LinkedIn

Curis Inc. (CRIS), a developer of cancer medicines, fell the most in more than three years after U.S. regulators placed a partial hold on a trial of its drug for solid tumors after a patient died from liver failure.

Curis dropped 21 percent to $3.08 at 10:16 a.m. New York time after falling to $3.03 in its biggest intraday decline since June 2010. The shares of the Lexington, Massachusetts-based company had risen 13 percent this year through yesterday.

Click here to read more.